Serum hepatitis B surface antigen titer and transient elastography in screening for insignificant fibrosis in HBeAg-positive chronic hepatitis B patients Ling-Bo Liang, Xia Zhu, Li-Bo Yan, Ling-Yao Du, Cong Liu, Li-Yu Chen, Juan Liao, Hong Tang Center of Infectious Disease, West China Hospital, West China School of Medicine, and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Peoples Republic of China Objective: To explore the predictive value of serum hepatitis B surface antigen (HBsAg) titer and transient elastography in screening for insignificant fibrosis in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients. Methods: We conducted a cross-sectional study of eligible patients treated from March 2012 to May 2013 at the West China Hospital of Sichuan University. Eligible patients underwent liver transient elastography and liver biopsy. We assessed the serum HBsAg level, serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) level, HBV genotypes, liver stiffness
Mouse monoclonal antibody raised against full length recombinant hepatitis B virus surface antigen. Recombinant protein corresponding to full length hepatitis B virus surface antigen. (MAB1691) - Products - Abnova
We offer to book Hepatitis B Surface Antigen (HbSAg) Quantitative Test online. View Hepatitis B Surface Antigen (HbSAg) Quantitative Test cost, pre test information and report availability on trutestlab.com. Home collection of blood sample is also available at our centers.
TRIVITRON HEALTHCARE PVT. LTD. - Exporter, Manufacturer, Distributor & Supplier of Biocard™ Hepatitis B Surface Antigen (Dip Stick) based in New Delhi, India
Hepatitis b surface antigen definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. Look it up now!
BACKGROUND: The kinetics of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue therapy has not been described. METHODS: We recruited 71 patients achieving persistent viro-logic suppression (Serum HBV DNA < 2,000 IU/mL) during lamivudine therapy for at least 10 years (10 patients for 15 years). Serum HBsAg (Elecsys HBsAg II) and HBV DNA levels (Cobas Taqman) were determined at baseline, year 5 and year 10. HBV genotype was determined by a line probe assay. RESULTS: The median age at lamivudine commencement was 38.6 (range 13.1 to 66.7) years. 57 patients (78.1%) were male and 43 (58.9%) were hepatitis B e antigen (HBeAg)-positive, with all 43 patients achieving HBeAg seroconversion after a median period of 2.82 (range 0.13 to 10.85) months. There was no significant difference in the median annual HBsAg decline rate from baseline to year 5 and from year 5 to 10 (0.350 and 0.359 log IU/mL/year respectively, p = 0.749). There was no difference in median annual ...
Yum, J. S., B. C. Ahn, H. J. Jo, D. Y. Kim, K. H. Kim, H. S. Kim, Y. C. Sung, J. Yoon, J. Morrey, and H. M. Moon. 2012. Use of pre-s protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection. Clin Vaccine Immunol 19:120-127. PMID22155769. ...
Hepatitis B virus (HBV) is one of the major causes of chronic hepatitis, cirrhosis and liver cancer. In combating HBV infections, HBV diagnosis and vaccination are therefore critical. The hepatitis B virus surface antigen (HBsAg) is a key target molecule in developing vaccines and diagnostic systems. To date, although HBsAg has been expressed in bacteria, yeasts and mammalian cells, there are still limitations in the existing ones, which leave the necessity for searching new HBsAg production methods. In this study, a simple phage display-based method was developed to produce the purified full-length HBsAg molecules for further immunization studies. For this purpose, the HBsAg coding gene was cloned into a pCANTAB5E phagemid vector and expressed on the surface of M13 filamentous phages. The HBsAg-expressing phage nanosystem was then used as immunization agent in BALB/cJ mice. The ELISA results for sera obtained from mice immunized with HBsAg-displaying phage particles revealed an immune response ...
Results: Of the 1000 samples 55 (5.5%) were found to be reactive, of which 87.3% (48/55) were positive for hepatitis B surface antibody, indicating immunity as a result of previous infection however, that does not exclude active infection with escaped mutant HBV. Nested PCR results showed the presence of hepatitis B viral DNA in all the 55 samples that were positive for core protein, which is in agreement with the hepatitis B surface antibody result ...
The aim of the study was to investigate correlations between intrahepatic hepatitis B virus total DNA, covalently closed circular DNA (cccDNA), and serum HBsAg in treatment-naive chronic hepatitis B and HBV related hepatocellular carcinoma (HCC). Liver tissues were taken from 42 HBV related HCC and 36 patients with chronic hepatitis B. A fraction of DNA extracted from liver tissue was digested with a plasmid-safe ATP-dependent DNase and used for HBV cccDNA detection. The remaining DNA was used for the detection of HBV total DNA and beta-globin, the latter of which is a housekeeping gene and quantified for normalization by real-time PCR. Quantitation of serum HBsAg was performed by a chemiluminescence assay. Serum HBsAg had positive correlations with serum HBV DNA (r?=?0.636, P ...
Hepatitis B Surface Antibody Anti Hbs testing locations in Tennessee. You can use this list to find local Hepatitis B Surface Antibody Anti Hbs testing.
TY - JOUR. T1 - The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells. AU - den Brouw, M.L.O.. AU - Binda, R.S.. AU - Geijtenbeek, T.B.H.. AU - Janssen, H.-G.. AU - Woltman, A.M.. PY - 2009. Y1 - 2009. U2 - 10.1016/j.virol.2009.07.015. DO - 10.1016/j.virol.2009.07.015. M3 - Article. VL - 393. SP - 84. EP - 90. JO - Virology. JF - Virology. SN - 0042-6822. IS - 1. ER - ...
TY - JOUR. T1 - Serological subtype (serotype) of hepatitis B virus surface antigen. AU - Iwasaki, Yoshiaki. AU - Tsuji, T.. PY - 1995/10. Y1 - 1995/10. UR - http://www.scopus.com/inward/record.url?scp=0029380199&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0029380199&partnerID=8YFLogxK. M3 - Article. VL - 53 Suppl. SP - 293. EP - 298. JO - Nippon rinsho. Japanese journal of clinical medicine. JF - Nippon rinsho. Japanese journal of clinical medicine. SN - 0047-1852. IS - Pt 2. ER - ...
Hepatitis B Surface Antigen Should Not Be the Only Sought Marker to Distinguish Blood Donors towards Hepatitis B Virus Infection in High Prevalence Area. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Background and AimChildren with chronic hepatitis B (CHB) are at high risk of progressive liver disease. It is suggested that a newly-identified panel of 16 microRNAs is important in the pathogenesis of CHB in children. Subviral hepatitis B surface antigen (HBsAg) particles are produced in large excess over infectious virions. Interestingly, circulating HBsAg particles have been shown to carry microRNAs. A thorough characterisation of the identified microRNAs and HBsAg over time in plasma from children with CHB may provide useful information about the natural course of childhood CHB. Patients and MethodsA cohort of 42 children with CHB was followed over time. Three to five blood samples were obtained from each child at minimum intervals of half a year; in total 180 blood samples. Plasma levels of the 16 microRNAs previously identified were analysed by quantitative real-time polymerase-chain-reaction. Plasma HBsAg was quantified using ARCHITECT® HBsAg assay. ResultsThe presence of 14/16 plasma
Surface antigen usually appears in the serum after an incubation period of 1 to 6 months following exposure to Hepatitis B virus and peaks shortly after onset of symptoms. It typically disappears within 1 to 3 months. Persistence of Hepatitis B surface antigen for greater than 6 months is a prognostic indicator of chronic Hepatitis B infection. ...
To assess the role of hepatitis B e antigen HBeAg and its interaction with hepatitis B surface antigen HBsAg on the development of hepatocellular carcinoma HCC, this case-control study included 361 age-and sex-matched pairs of patients with histologically proven HCC and healthy control subjects. HBsAg, HBeAg and antibody to HBeAg anti-HBe were...
Hepatitis B viral mutants can emerge in patients as a result of selection pressure from either immune response or treatment options. Mutations that occur within the immunodominant epitopes of hepatitis B surface antigen (HBsAg) allow mutant virus to propagate in the presence of a neutralizing immune response, while wild-type virus is reduced to undetectable levels. HBsAg mutants present as false-negative results in some immunoassays. An understanding of immunoassay reactivity with HBsAg mutants is key to establishing an appropriate testing algorithm for hepatitis B virus detection programs ...
Hepatitis B viral mutants can emerge in patients as a result of selection pressure from either immune response or treatment options. Mutations that occur within the immunodominant epitopes of hepatitis B surface antigen (HBsAg) allow mutant virus to propagate in the presence of a neutralizing immune response, while wild-type virus is reduced to undetectable levels. HBsAg mutants present as false-negative results in some immunoassays. An understanding of immunoassay reactivity with HBsAg mutants is key to establishing an appropriate testing algorithm for hepatitis B virus detection programs.
臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。. To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of "NTU Repository" with "Academic Hub" to form NTU Scholars.. ...
Background & aim: Hepatitis B virus (HBV) infection is a major global health concern. According to the statistics, the prevalence of this infection is moderate in Iran. Pregnant mothers, who are infected with the virus (virus carriers), can transmit the infection to their fetus. This study aimed to determine the prevalence of hepatitis B surface antigen (HBsAg) and its influencing factors in pregnant women, referring to healthcare centers of Dehloran, Iran. Methods:In this descriptive, cross-sectional study, the sample consisted of all pregnant women with medical records, referring to healthcare centers of Dehloran city for prenatal care during 2011-2012. Census sampling was applied and subjects medical records were reviewed. Demographic and pregnancy-related data, and HBV test results were recorded. For data analysis, descriptive statistics, t-test and Fishers exact test were applied, using SPSS version 16.0. P-value | 0.05 was considered statistically significant. Results: In this study, the medical
Major hydrophilic region in genomic HBV extending from aa99 to aa169, clustered with a highly conformational epitope, is critical to the antigenicity of hepatitis B surface antigen (HBsAg) and may affect the diagnosis of HBV in HBV screening test. So, this study aimed to characterize variants of S gene product of hepatitis B virus (HBV) isolated from patients with overt or occult HBV infection in north-eastern Egypt. The study included sera of two different groups of volunteer blood donors (VBDs), 82 with overt HBV that were positive for HBsAg and anti-HBc and 343 donors negative for HBsAg eligible for donation. Of the latter group, only 44 were positive for anti-HBc. All anti-HBc positive sera were subjected to HBV DNA detection and partial sequence analysis targeting the HBV S gene. HBV DNA was detected in 22.7 % of HBsAg-/anti-HBc + (10/44 patients) and in 90 % of HBsAg + donors (74/82 patients) with significant statistical difference (P = 0.0001). Phylogenetic analysis showed that HBV strains
BACKGROUND Post-exposure prophylaxis administered to infants shortly after birth prevents approximately 90% of cases of perinatal hepatitis B virus (HBV) transmission. The Advisory Committee on Immunization Practices recommends that all pregnant women be tested for hepatitis B surface antigen (HBsAg) at an early prenatal visit during each pregnancy to detect active infection with HBV. This study sought to determine the proportion and characteristics of pregnant women tested\not tested according to Advisory Committee on Immunization Practices recommendations. METHODS We analyzed MarketScan databases to assess prenatal HBsAg testing among women with commercial and Medicaid health care coverage according to demographic and clinical characteristics. Pregnant women 15-44 years of age continuously enrolled in a health plan in the MarketScan database during 2013 and 2014 and with a live birth in 2014 were included. RESULTS Among commercially insured women, 239,955 (87.7%) received HBsAg testing and 59.6%
Introduction Occult hepatitis B virus (HBV) infection, so-called occult B infection (OBI), is defined by the recognition of HBV-DNA in the absence of serum hepatitis B surface antigen (HBsAg). The HBV-DNA genome in OBI is fully replication competent and produced in the liver, characteristically with low-level HBV-DNA fluctuations in the bloodstream. The OBI status remains between chronic (HBsAg +) and resolved (anti-HBs +) phases in the natural history of HBV infection. Methods The clinical interest in OBI has increased because of its potential for overt HBV reactivation under immunosuppression as well as for HBV transmission, well established in recipients of blood transfusions and/or organ transplants. Results Given the shared transmission routes for HIV and HBV, earlier reports claimed that OBI was more frequent in AIDS patients. By contrast, the current scenario shows that OBI is negligible in the HIV population. One explanation is that HBV immunization and recall vaccination campaigns have ...
BACKGROUND Delta virus (HDV)-related chronic hepatitis is difficult to treat. AIMS To evaluate the efficacy of lamivudine 100 mg daily on serum HDV-RNA, hepatitis D virus antibodies and alanine aminotransferase levels, liver histology, and on hepatitis B surface antigen seroconversion. METHODS Thirty-one hepatitis B surface antigen-positive, HDV-RNA-positive patients with ALT | or = 1.5 upper normal level and compensated liver disease were randomized (1:2 ratio) to placebo (group A, n = 11) or lamivudine (group B, n = 20) for 52 weeks; thereafter, all patients were given lamivudine for 52 weeks and followed up for 16 weeks. RESULTS Twenty-five patients (81%) completed the study. No patient was HDV-RNA-negative at week 52; three patients (11%) were negative at week 104. Two of them remained HDV-RNA-negative at week 120, and one lost the hepatitis B surface antigen without seroconversion. Paired pre-treatment and week 104 liver biopsies were available from 19 patients: of which three of seven (43%)
Proliferative responses to hepatitis B surface antigen (HBsAg). Proliferative responses to HBsAg, measured as counts per minute (cpm) of 3H-thymidine incorporat
Farzadegan, H.; Harbour, C.; Ala, F., 1979: The prevalence of hepatitis B surface antigen and its antibody in blood donors and high risk groups in Iran
Gentaur molecular products has all kinds of products like :search , AbD \ GOAT ANTI HEPATITIS B SURFACE ANTIGEN AD_AY HRP-POLYCLONAL ANTIBODY \ 4940-1484 for more molecular products just contact us
AMH Nationwide offers Hepatitis B Surface Antigen tests at their facilities. Call us at ☎ (888) 493-2521 to find more information about a lab near you!
The details of bibliography - Hepatitis B surface antigen is not associated with chronic renal disease in Aboriginal Australians [letter]
Persons with chronic hepatitis B virus (HBV) infection are at high risk for chronic liver disease and are a major reservoir of HBV infection. Foreign-born populations from Africa, Asia, and the Pacific Islands have high rates of chronic HBV infection (i.e., HBsAg prevalence of ,8%). During delivery of recommended hepatitis B vaccination services (e.g., HBsAg screening of pregnant women and serologic testing to assess susceptibility), vaccination providers will identify persons who are HBsAg positive. These persons require counseling and medical management for chronic HBV infection to reduce their risk for chronic liver disease. Their susceptible household, sex, and needle-sharing contacts also should be vaccinated against hepatitis B. Extending screening, referral, and contact vaccination services to persons identified as HBsAg positive can help prevent serious sequelae in persons with chronic infection and enhance vaccination strategies to eliminate HBV transmission. This appendix provides ...
Bio-Rad Antibodies (formerly AbD Serotec) is the research antibody division of Bio-Rad, the worlds leading life science company.
The detection of anti-HBs is indicative of a prior immunologic exposure to the antigen or vaccine. To determine immune status as ≥10 mIU/mL as per CDC guidelines, please order Hepatitis B Surface Antibody, Quantitative.. ...
Screening is the process of identifying people who appear healthy but may be at increased risk of a disease or condition. Most often, the timing of the infection is a critical point for infectious disease screening, as a failure of early detection and timely intervention is a missed opportunity for prompt treatment and prevention.. Our Screening panel includes Hepatitis B surface antigen (HBsAg), Hepatitis C Virus (HCV), Retroviral screening (RVS), H.Pylori, Typhoid (Widal), Stool microscopy, and Urine microscopy.. Hepatitis B surface antigen (HBsAg): With the increasing number of hepatitis B infection, unknown to many who are being infected with the virus, the need for Hepatitis B surface antigen (HBsAg) remains strong. The test is targeted to check the presence of Hepatitis B Virus (HBV) in the blood.. Hepatitis C Virus (HCV) antibody test: HCV is transmitted in a manner similar to HBV. Most cases of hepatitis C are caused by blood transfusion. HCV is found in as many as 8% of blood donors ...
... Find a lab near you and save when you get blood work directly through Personalabs!
Mouse monoclonal Hepatitis B Virus Surface Antigen antibody [HB12] validated for ELISA. Immunogen corresponding to recombinant full length protein
Hepatitis B Virus Surface Antigen小鼠单克隆抗体经ELISA, ICC实验严格验证。所有产品均提供质保服务,中国75%以上现货。
Chronic hepatitis was diagnosed on liver biopsy of 76 patients; 52 (68%)had HBsAg. Of the 52 patients with HBsAg, 23% had HBsAg shown by immunofluorescence on the liver, while it could not be detected with radioimmunoassay on the serum; 77% had HBsAg detectable in liver and in serum, and none had HBsAg in serum only. HBsAg was detected more frequently in chronic aggressive hepatitis and active cirrhosis than in chronic persistent hepatitis and cirrhosis with little activity. No correlation was found in the different forms of chronic hepatitis between the HBsAg status on the one hand, and levels of transaminases, gammaglobulins, and auto-antibodies on the other. Acute hepatitis was diagnosed on liver biopsy of 24 patients; 50% had HBsAg. Liver tissue positivity was very low in the fully developed stage compared to serum positivity. In 146 patients with other liver ailments, both liver and serum were negative for HBsAg.. ...
The standard hepatitis B surface Ag (HBsAg) vaccine fails to induce anti-hepatitis B surface Abs in 5-10% of healthy subjects, a phenomenon known as HBsAg nonresponsiveness, which is closely related to HLA class II alleles and impaired Th cell responses to HBsAg in these subjects. We hypothesized that GM-CSF, a potent adjuvant in enhancing the Ag-presentation activity of APCs, might help to generate Th cell responses in nonresponders, subsequently providing help for B cells to produce anti-hepatitis B surface Abs. We used a thermosensitive biodegradable copolymer (hydrogel) system to codeliver HBsAg and GM-CSF to achieve maximal local cytokine activity at the injection site. In responder mouse strains, hydrogel-formulated HBsAg plus GM-CSF (Gel/HBs+GM) vaccine elicited much greater anti-hepatitis B surface Ab titers and Th cell proliferative responses than a commercial aluminum-formulated HBsAg vaccine or free HBsAg. The adjuvant effect of the Gel/HBs+GM vaccine was dependent upon the local ...
References for Abcams Anti-Hepatitis B Virus Surface Antigen antibody [HB6] (HRP) (ab2042). Please let us know if you have used this product in your…
Creative Diagnostics Supplies You High Quality Hepatitis B Virus Test,Hepatitis B Surface Antigen,our Products Have Already Got CD-DIA Test.
To observe the long term response to first-line antiretroviral therapy (ART) in HIV and hepatitis B virus (HBV) co-infected patients in Ghana and explore predictors of poor clinical outcomes. Methods: Retrospective cohort study of hepatitis B surface antigen (HBsAg) positive and negative patients receiving predominantly NNRTI-based ART with lamivudine plus either zidovudine or stavudine for up to seven years. Cox proportional hazards and Kaplan Meier survival analyses compared clinical outcomes and identified baseline characteristics predictive of poor outcomes. A mixed effects model compared changes in CD4 counts. Results: A total of 299 HBsAg-positive and 1869 HBsAg-negative patients started ART between 2004 and 2008. Over a median 35 months of follow-up, HBsAg-positive patients were more likely to die or default care than HBsAg-negative patients, aHR 1.36 (95% CI, 1.03e1.80). HBsAg-positive patients were also more likely to develop Grade 3/4 hepatotoxicity than HBsAg-negative patients, HR ...
Hepatitis B virus (HBV) is both a hepatotrophic and a lymphotrophic virus. By contrast with the role of HBV infection in hepatocarcinogenesis, data for the causal association of HBV infection and development of non-Hodgkin lymphoma (NHL) are scarce. Several case-control studies have shown a higher prevalence of chronic HBV infection in patients with NHL than in patients in various control groups (historical controls, blood donors, and hospital controls), with an odds ratio of about 2·5.1 However, there have been few cohort studies. A cohort study from the USA, which included about 210 000 people, with a follow-up of up to 7 years, showed that chronic HBV infection increased risk of development of NHL by almost three times.2 A population-based study of long-term mortality for up to 29 years in blood donors testing positive for serum hepatitis B surface antigen in England and Wales showed that risk of NHL increased after the first decade of follow-up, along with a clear increase in liver-related ...
Reactive Hepatitis B Surface Antigen will reflex to the Hepatitis B Surface Antigen Confirmatory neutralization test for an additional charge. Reactive Hepatitis B Core Antibody will reflex to the Hepatitis B Core IgM antibody for an additional charge ...
Hepatitis Research and Treatment is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to all aspects of hepatitis.
Screening is the process of identifying people who appear healthy but may be at increased risk of a disease or condition. Most often, the timing of the infection is a critical point for infectious disease screening, as failure of early detection and timely intervention is a missed opportunity for prompt treatment and prevention. This panel includes:. Hepatitis B surface antigen (HBsAg): With increasing number of hepatitis B infection, unknown to many who are being infected with the virus, the need for Hepatitis B surface antigen (HBsAg) remains strong. The test is targeted to check presence of Hepatitis B Virus (HBV) in the blood.. Hepatitis C Virus (HCV) antibody test: HCV is transmitted in a manner similar to HBV. Most cases of hepatitis C are caused by blood transfusion. HCV is found in as many as 8% of blood donors worldwide. The incubation period is 2 to 12 weeks after exposure and the clinical manifestations of the illness parallel those of HBV. However unlike HBV, HCV infection is chronic ...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
Study end-points: The major end-point: hepatitis B reactivation in NHL patients---defined by higher than 10-fold increase of serum HBV DNA level and/or reappearance of HBeAg in the serum during and within 6 months after chemotherapy. The minor end-point I : events of hepatic failure and death---defined by jaundice with hepatic encephalopathy. The minor end-point II: the response rate and survival rate in HBsAg-positive NHL patients receiving lamivudine prophylaxis and treatment.) ...
Hello, I am a microbiological graduate student at Mahidol University. Now I am doing my thesis under the topicProduction and Characterization of Monoclonal Antidodies against Hepatitis B surface antigen. After getting desirable clones,I have a big problem.For characterization of those MAbs,I do not have subtype panel of Hepatitis B surface antigen;only subtype adr and adw that I have. I would like to have other subtypes; ayr and ayw. Anyone who can advise me about source or suppliers of all the subtypes above or available in hand. Please inform me. I am very truly need your help. Thanks in advance. TAM ...
ABSTRACT. This study aimed to investigate the serum HBsAg level in patients with HDV co-infection, its relationship with HBV DNA and HDV RNA levels and with the fibrosis stage. 19 patients were considered. Patients with hepatitis C or HIV co-infection were excluded. HBV DNA and HDV RNA quantization was done using COBAS Taq Man HBV test (Roche Diagnostics) and AmpliSensHDV test (Inter Lab Service), respectively. The HBsAg level was measured by the Architect HBsAgQT (Abbott Laboratories) assay. Statistical relationships were estimated by the Pearson correlation coefficient r.. In patients with HDV co-infection no correlation between HBsAg level and HBV viral load was detected. The correlation between HBsAg and HDV RNA levels (r=0.663, p=0.002) as well as between HDV RNA level and fibrosis stage (r=0.50, p,0.05) was significant.. The correlation between HBsAg level and the fibrosis stage was less significant (r=0.42, p=0.07).. We conclude that in patients with HDV co-infection:. i. HBsAg level did ...